XML 30 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - shares
 12 Months Ended
Dec. 31, 2021
Mar. 24, 2022
Cover [Abstract]    
Document Type 10-K  
Amendment Flag false  
Document Period End Date Dec. 31, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus FY  
Entity Registrant Name Adagio Therapeutics, Inc.  
Entity Central Index Key 0001832038  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Interactive Data Current Yes  
Current Fiscal Year End Date --12-31  
Entity Filer Category Non-accelerated Filer  
Entity Well-known Seasoned Issuer No  
ICFR Auditor Attestation Flag false  
Entity Common Stock, Shares Outstanding   109,675,173
Entity Shell Company false  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol ADGI  
Security Exchange Name NASDAQ  
Entity File Number 001-40703  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1403134  
Entity Address, Address Line One 1601 Trapelo Road  
Entity Address, Address Line Two Suite 178  
Entity Address, City or Town Waltham  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02451  
City Area Code 781  
Local Phone Number 819-0080  
Document Annual Report true  
Document Transition Report false  
Documents Incorporated by Reference

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the Registrant’s definitive proxy statement, to be filed pursuant to Regulation 14A under the Securities Exchange Act of 1934, for its 2022 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.

  
Auditor Name PricewaterhouseCoopers LLP  
Auditor Firm ID 238  
Auditor Location Boston, Massachusetts